EP3154975A1 - Phosphate de ténofovir disoproxil, et composition pharmaceutique de celui-ci comprenant un délitant de sel non métallique et un lubrifiant de sel non-métallique - Google Patents

Phosphate de ténofovir disoproxil, et composition pharmaceutique de celui-ci comprenant un délitant de sel non métallique et un lubrifiant de sel non-métallique

Info

Publication number
EP3154975A1
EP3154975A1 EP15814377.6A EP15814377A EP3154975A1 EP 3154975 A1 EP3154975 A1 EP 3154975A1 EP 15814377 A EP15814377 A EP 15814377A EP 3154975 A1 EP3154975 A1 EP 3154975A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
metallic salt
formula
disintegrant
lubricant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15814377.6A
Other languages
German (de)
English (en)
Other versions
EP3154975A4 (fr
Inventor
Jung Hyun Cho
Young Keun Choi
Hyung Seo Kim
Kyeong Soo Kim
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of EP3154975A1 publication Critical patent/EP3154975A1/fr
Publication of EP3154975A4 publication Critical patent/EP3154975A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Definitions

  • the present disclosure relates to a tenofovir disoproxil phosphate (hereinafter, also referred to as "TDP"), a pharmaceutical composition thereof comprising tenofovir disoproxil or pharmaceutically acceptable salt thereof, a non-metallic salt disintegrant and a non-metallic salt lubricant, and more particularly, to a tenofovir disoproxil phosphate with high bioavailability and stability, and a pharmaceutical composition thereof comprising a non-metallic salt disintegrant and a non-metallic salt lubricant.
  • TDP tenofovir disoproxil phosphate
  • Tenofovir Systematic (IUPAC) name; ( ⁇ [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy ⁇ methyl)phosphonic acid) represented by Formula A as a nucleotide analog is known to suppress the proliferation of viruses such as HIV and HBV and thus is effectively used in treatment of HIV-1 infection and chronic hepatitis B.
  • IUPAC Systematic (IUPAC) name; ( ⁇ [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy ⁇ methyl)phosphonic acid
  • tenofovir has low bioavailability (Antimacrobial Agents and Chemotherapy, July 1998, p.1568-1573).
  • tenofovir disoproxil compound represented by Formula 1
  • it is still difficult to formulate tenofovir disoproxil due to its poor stability.
  • various efforts have been made to develop a salt form of tenofovir disoproxil and prepare a formulation therefrom.
  • tenofovir disoproxil fumarate WO 1999-005150
  • tenofovir disoproxil succinate WO 2010-142761
  • tenofovir disoproxil aspartate WO 2014-035064
  • WO 1999-005150 discloses preparing a tablet including tenofovir disoproxil fumarate by wet granulation.
  • wet granulation method may lower the stability of tenofovir disoproxil due to the influence of moisture, which has been experimentally confirmed by the inventors of the present application.
  • the present invention provides a novel salt of tenofovir disoproxil that has pharmacokinetic advantages, higher bioavailability than tenofovir disoproxil fumarate, and that has lower generation of related compounds, and a pharmaceutical composition with higher stability of tenofovir disoproxil.
  • a pharmaceutical composition including the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; a non-metallic salt disintegrant; and a non-metallic salt lubricant.
  • a method of preparing the above-described pharmaceutical composition includes: (a) preparing a granule by granulating a mixture of the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; (b) preparing a mixed granule by mixing the granule prepared in (a) with a non-metallic salt disintegrant and adding a non-metallic salt lubricant thereto; and (c) formulating the mixed granule prepared in (b).
  • tenofovir disoproxil phosphate may have higher bioavailability and lower generation of related compounds than conventional tenofovir disoproxil fumarate.
  • a pharmaceutical composition including tenofovir disoproxil or a pharmaceutically acceptable salt thereof, a non-metallic salt disintegrant, and a non-metallic salt lubricant may remarkably improve the stability of tenofovir disoproxil compared to conventional drug formulations. Therefore, the pharmaceutical composition may have high bioavailability and stability.
  • FIG. 1 illustrates graphs of the amounts of generated unknown related compounds A and B as a result of a stability test at 60°C with regard to a compound of Formula 1 and various pharmaceutically acceptable salts thereof, wherein TD denotes tenofovir disoproxil, TDF denotes tenofovir disoproxil fumarate, TDO denotes tenofovir disoproxil orotate, and TDP denotes tenofovir disoproxil phosphate.
  • a phosphate of a compound represented by Formula 1 is provided.
  • the phosphate of the compound of Formula 1 may be a tenofovir disoproxil phosphate, which is a salt resulting from about 1:1 ionic bonding of phosphoric acid and tenofovir disoproxil free base.
  • the tenofovir disoproxil phosphate may be prepared by a method that includes:
  • the tenofovir disoproxil free base may be purchased or prepared using a known method.
  • the amount of phosphoric acid relative to tenofovir disoproxil free base may be in the range of about 1 to 3 equivalents, and in some embodiments, about 1.1 to about 1.5 equivalents.
  • the amount of water used as a reaction solvent may be in the range of about 5 mL to about 100 mL, and in some embodiments, about 10 mL to about 50 mL, based on 1 g of the tenofovir disoproxil free base.
  • a reaction temperature in the heating and stirring may be room temperature or a temperature less than or approximately equal to a boiling point temperature of the reaction solvent, i.e., 100°C or lower, and in some embodiments, may be in the range of about 40°C to about 60°C.
  • the reaction time in the heating and stirring may vary depending on the reaction temperature and may be, for example, in the range of about 10 hours to about 15 hours.
  • the tenofovir disoproxil phosphate may have remarkably high bioavailability and high stability compared to conventional other salts of tenofovir disoproxil. Accordingly, a pharmaceutical composition including the tenofovir disoproxil phosphate may be provided as a pharmaceutical product with ensured efficacy and stability.
  • a pharmaceutical composition including: the compound of Formula 1 or a pharmaceutically acceptable salt thereof; a non-metallic salt disintegrant; and a non-metallic salt lubricant.
  • Pharmacologically active ingredients of the pharmaceutical composition may include a compound of Formula 1 or a pharmaceutically acceptable salt thereof.
  • the compound of Formula 1 is known to be effective in treatment or prevention of a viral infection, caused by a retrovirus, HIV, SIV, GALV, hepadnavirus, HBV, etc. in a human or animal (WO 1999-005150).
  • the pharmaceutically acceptable salt of the compound of Formula 1 may be an acid addition salt, including an inorganic acid salt and an organic acid salt.
  • the acid addition salt may be phosphate, fumarate, succinate, or orotate.
  • the acid addition salt may be phosphate or orotate.
  • embodiments are not limited thereto.
  • the amount of the compound of Formula 1 or a pharmaceutically acceptable salt thereof may be in the range of about 1.0 wt% to about 80 wt%, and in some embodiments, about 1.0 wt% to about 50wt%, based on a total weight of the pharmaceutical composition. However, embodiments are not limited thereto.
  • a disintegrant which is an ingredient added to facilitate swelling of a solid, compressed drug formulation, is an essential excipient for the preparation of general solid, compressed formulations. Disintegrants may facilitate absorption of pharmacological active ingredients of a drug formulation in the body by disintegrating the drug formulation into smaller particles when the drug formulation is administered into the body.
  • Disintegrants available in the field of pharmaceutics include metallic salt disintegrants and non-metallic salt disintegrants.
  • a metallic salt in a metallic-salt ingredient may facilitate the generation of unknown related compounds A and B as major decomposition products of the compound of Formula 1, whereas a non-metallic salt disintegrant does not facilitate generation of the unknown related compounds A and B.
  • the pharmaceutical composition according to an embodiment of the present disclosure may include a non-metallic salt disintegrant.
  • non-metallic salt disintegrant refers to a disintegrant not including a metallic component, i.e., excluding a metallic salt disintegrant such as sodium alginate, sodium carboxymethyl cellulose, sodium croscarmellose, and sodium starch glycolate.
  • a metallic salt disintegrant such as sodium alginate, sodium carboxymethyl cellulose, sodium croscarmellose, and sodium starch glycolate.
  • Non-limiting available examples of the non-metallic salt disintegrant are crospovidone, low-substituted hydroxypropyl cellulose, alginic acid, or pregelatinized starch.
  • Use of the non-metallic salt disintegrant may enable preparation of a tenofovir disoproxil or a salt thereof-containing pharmaceutical composition with improved storage stability.
  • the non-metallic salt disintegrant may be crospovidone, low-substituted hydroxypropyl cellulose, alginic acid, pregelatinized starch, or any combinations thereof.
  • the non-metallic salt disintegrant may be crospovidone, low-substituted hydroxypropyl cellulose, or any combinations thereof.
  • embodiments are not limited thereto.
  • non-metallic salt disintegrants may be used alone or in a combination of at least two.
  • the amount of the non-metallic salt disintegrant may be in the range of about 0.001 parts to about 10 parts by weight, and in some embodiments, about 0.005 parts to about 5 parts by weight, and in some other embodiments, about 0.01 parts to about 1 part by weight, based on 1 part by weight of the pharmacologically active ingredient.
  • embodiments are not limited thereto.
  • the pharmaceutical composition may have advantages such as a granule density appropriate for tableting, maintenance of an appropriate hardness and a standard friability, and prevention of state change caused by moisture.
  • a lubricant which is an ingredient added to facilitate the process of compressing granules, is an essential excipient for the preparation of general solid compressed formulations.
  • Lubricants may facilitate flowability of a granule and powder to easily fill in a die, may reduce friction between granules and powder themselves and friction among a die, punch, granules and powder, and may facilitate tablet compressing and discharge from a die.
  • Lubricants that are available in the field of pharmaceutics include metallic salt lubricants and non-metallic salt lubricants.
  • a metallic salt in a metallic salt lubricant may facilitate generation of unknown related compounds A and B which are major decomposition products of the compound of Formula 1, whereas a non-metallic salt lubricant does not facilitate generation of the unknown related compounds A and B.
  • the pharmaceutical composition according to an embodiment of the present disclosure may include a non-metallic salt lubricant.
  • non-metallic salt lubricant refers to a lubricant not including a metallic component, i.e., which excludes a metallic salt lubricant such as calcium stearate, magnesium stearate, sodium stearyl fumarate, and zinc stearate.
  • a metallic salt lubricant such as calcium stearate, magnesium stearate, sodium stearyl fumarate, and zinc stearate.
  • Non-limiting available examples of the non-metallic salt lubricant are fatty acid esters, fatty acids, alcohols, oils, fumaric acid, polyethylene glycol, polytetrafluoroethylene, talc, or a mixture thereof.
  • Use of the non-metallic salt lubricant may enable preparation of a tenofovir disoproxil or a salt thereof-containing pharmaceutical composition with improved storage stability.
  • the non-metallic salt lubricant may be fatty acid esters (for example, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl trimyristearate, glyceryl tristearate, or sucrose fatty acid ester); fatty acids and alcohols thereof (for example, palmitic acid, palmitoyl alcohol, stearic acid, or stearyl alcohol); oils (for example, hydrogenated castor oil, mineral oil, or hydrogenated vegetable oil); fumaric acid; polyethylene glycol (for example, PEG 4000 or PEG 6000); polytetrafluoroethylene; talc; or any combinations thereof.
  • fatty acid esters for example, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl trimyristearate, glyceryl tristearate, or sucrose fatty acid ester
  • the non-metallic salt lubricant may be sucrose fatty acid ester, stearic acid, hydrogenated vegetable oil, talc, glyceryl behenate, glyceryl palmitostearate, starch, PEG 6000, or any combinations thereof.
  • the non-metallic salt lubricant may be sucrose fatty acid ester, stearic acid, or any combinations thereof. However, embodiments are not limited thereto.
  • non-metallic salt lubricants may be used alone or in a combination of at least two.
  • the amount of the non-metallic salt lubricant may be in the range of about 0.0005 parts to about 5 parts by weight, and in some embodiments, about 0.001 parts to about 1 parts by weight, and in some other embodiments, about 0.005 parts to about 0.5 parts by weight, based on 1 part by weight of the pharmacologically active ingredient.
  • embodiments are not limited thereto.
  • a lubricant may have high water repellency, and thus, when used in excess, may lead to unexpected results such as a disintegration delay or a dissolution reduction of pharmacologically active ingredients.
  • the pharmaceutical composition may further include a pharmaceutically acceptable additive and may be obtained in a variety of forms.
  • the pharmaceutical composition may be, but is not limited to, an oral drug formulation.
  • the oral drug formulation may be a powder, a tablet, a pill, a capsule, liquid, a suspension, an emulsion, syrup, or a granule.
  • the oral drug formulation may be in the form of a tablet or capsule.
  • embodiments are not limited thereto.
  • the oral drug formulation may further include, a diluent, a binder, or the like as a pharmaceutically acceptable additive.
  • Non-limiting examples of the diluents are microcrystalline cellulose, lactose, mannitol, and calcium phosphate.
  • Non-limiting examples of the binder are pregelatinized starch, povidone, hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), and sodium carboxymethyl cellulose.
  • the amount of the diluent may be in the range of about 0.1 parts to about 100 parts by weight based on 1 part by weight of the pharmacologically active ingredient.
  • the amount of the binder may be in the range of about 0.01 part to about 10 parts by weight based on 1 part by weight of the pharmacologically active ingredient.
  • a method of preparing a pharmaceutical composition includes: (a) granulating a mixture of a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive to prepare a granule; (b) mixing the granule prepared in step (a) with a non-metallic salt disintegrant and adding a non-metallic salt lubricant thereto to prepare a mixed granule; and (c) formulating the mixed granule prepared in step (b).
  • the pharmaceutical composition may be prepared as granules by i) dry granulation using compaction granulation or ii) wet granulation using water added as a binding solution.
  • the pharmaceutical composition may be prepared as tablets by adding a non-metallic salt disintegrant to the resulting granules and mixing together, adding a non-metallic salt lubricant to the resulting mixture and finally mixing together, and then tableting the final mixture using a tablet press.
  • the pharmaceutical composition according to any of the embodiments may be effectively used in treatment of HIV-1 infection and chronic hepatitis B due to the inclusion of a compound of Formula 1 that is known to be effective in treatment or prevention of at least one viral infection caused by a retrovirus, HIV, SIV, GALV, hepadnavirus, HBV, etc. in a human or animal.
  • the pharmaceutical composition according to any of the embodiments may also suppress generation of impurities (unknown related compounds A and B) to be within about 0.2% when stored in an airtight container such as a high-density polyethylene (HDPE) bottle under the stressed condition at about 60°C for about 4 weeks or under the accelerated condition at about 40°C and a a relative humidity (RH) of about 75% for about 3 months, satisfying a requirement of the Guidelines of the International Conference on Harmonization (ICH) that unknown related compounds is about 0.2wt% or less in the case of 3-month storage under the ICH accelerated condition. Therefore, the pharmaceutical composition according to any of the embodiments may be manufactured as a pharmaceutical product with ensured high stability of the compound of Formula 1.
  • an airtight container such as a high-density polyethylene (HDPE) bottle under the stressed condition at about 60°C for about 4 weeks or under the accelerated condition at about 40°C and a a relative humidity (RH) of about 75% for about 3 months
  • Tablets were prepared using tenofovir disoproxil phosphate (TDP, available from HANMI FINE CHEMICAL CO., LTD, Korea), microcrystalline cellulose (available from MINGTAI), lactose (WON POONG PHARM CO.
  • TDP tenofovir disoproxil phosphate
  • MINGTAI microcrystalline cellulose
  • lactose WON POONG PHARM CO.
  • pregelatinized starch available from Roquette
  • sucrose fatty acid ester available from STEARINERIEDUBOIS
  • a non-metallic salt disintegrant selected from alginic acid (available from FMC), low-substituted hydroxypropyl cellulose (available from SHIN-ETSU), crospovidone (available from BASF), and pregelatinized starch (available from Roquette), according to the compositions in Table 1, in which the amounts of ingredients are represented in milligram (mg).
  • TDP microcrystalline cellulose
  • lactose lactose
  • pregelatinized starch were each sieved, mixed together, dry-granulated using a roller compactor, and then were established in an oscillator to obtain granules.
  • the resulting granules were mixed with a disintegrant and then finally with sucrose fatty acid ester that was sieved through a sieve having a mesh size of 30.
  • the resulting final mixture was pressed using a tablet press (available from Sejong Pharmatech Co., Ltd., Korea) according to a common method to form tablets having a hardness of about 10 kp to about 15 kp.
  • Tablets including a metallic salt disintegrant were prepared in the same manner as in Examples 1 to 4, according to the compositions in Table 2, in which the amounts of ingredients are represented in milligram (mg).
  • Tablets were prepared using TDP (available from HANMI FINE CHEMICAL CO., LTD, Korea), and microcrystalline cellulose (available from MINGTAI), lactose (WON POONG PHARM CO. LTD, Korea), pregelatinized starch (available from Roquette), crospovidone (available from BASF), and a non-metallic salt lubricant selected from sucrose fatty acid ester (available from DAI-ICHI KOGYO SEIYAKU, Japan), stearic acid (available from Emeryoleochemicals) hydrogenated vegetable oil (Lubritab, available from JRS Pharma), and talc (available from Nippon talc corp.) , according to the compositions in Table 3, in which the amounts of ingredients are represented in milligram (mg).
  • TDP microcrystalline cellulose
  • lactose lactose
  • pregelatinized starch were each sieved, mixed together, dry-granulated using a roller compactor, and then were established in an oscillator to obtain granules.
  • the resulting granules were mixed with crospovidone and then finally with a lubricant that was sieved through a sieve having a mesh size of 30.
  • the resulting final mixture was pressed using a tablet press (available from Sejong Pharmatech Co., Ltd., Korea) according to a common method to form tablets having a hardness of about 10 kp to about 15 kp.
  • Tablets were prepared in the same manner as described above using TDP (available from HANMI FINE CHEMICAL CO., LTD, Korea), and microcrystalline cellulose (available from MINGTAI), lactose (WON POONG PHARM CO. LTD, Korea), pregelatinized starch (available from Roquette), crospovidone (available from BASF), and a non-metallic salt lubricant selected from glyceryl behenate (Compritol 888 ATO, available from Gattefosse), glyceryl palmitostearate (Compritol HD5, available from Gatefosse), starch (available from Roquette), and PEG 6000 (available from Sanyo chemical), according to the compositions in Table 4, in which the amounts of ingredients are represented in milligram (mg).
  • TDP available from HANMI FINE CHEMICAL CO., LTD, Korea
  • microcrystalline cellulose available from MINGTAI
  • lactose WON POONG PHARM CO. LTD, Korea
  • pregelatinized starch available
  • Tablets were prepared in the same manner as described above using TDP (available from HANMI FINE CHEMICAL CO., LTD, Korea), microcrystalline cellulose (available from MINGTAI), lactose (WON POONG PHARM CO. LTD, Korea), pregelatinized starch (available from Roquette), crospovidone (available from BASF), and a non-metallic salt lubricant selected from glyceryl monostearate (Capmul GMS-50), palmitoyl alcohol (Landzinternational Company, China), stearyl alcohol (available from Lubrizol Advanced Materials, U.S.A.), hydrogenated castor oil (available from BASF), mineral oil (Alfa Aesar, U.S.A.), fumaric acid (available from Merck), and silicon dioxide (Grace Davison, U.S.A.), according to the compositions in Table 5, in which the amounts of ingredients are represented in milligram (mg).
  • TDP available from HANMI FINE CHEMICAL CO., LTD, Korea
  • Tablets including a metallic salt lubricant were prepared in the same manner as in Examples 5 to 19, according to the compositions in Table 6, in which the amounts of ingredients are represented in milligram (mg).
  • Tablets were prepared using TDP (available from HANMI FINE CHEMICAL CO., LTD, Korea), microcrystalline cellulose (available from MINGTAI), lactose (WON POONG PHARM CO. LTD, Korea), pregelatinized starch (available from Roquette), sucrose fatty acid ester (available from STEARINERIEDUBOIS), and a non-metallic salt disintegrant selected from alginic acid (available from FMC), low-substituted hydroxypropyl cellulose (available from SHIN-ETSU), crospovidone (available from BASF), and pregelatinized starch (available from Roquette), according to the compositions in Table 7, in which the amounts of ingredients are represented in milligram (mg).
  • TDP available from HANMI FINE CHEMICAL CO., LTD, Korea
  • microcrystalline cellulose available from MINGTAI
  • lactose WON POONG PHARM CO. LTD, Korea
  • pregelatinized starch available from Roquette
  • sucrose fatty acid ester available
  • TDP microcrystalline cellulose
  • lactose lactose
  • pregelatinized starch were each sieved, mixed together, wet-granulated according to a common method with purified water, and then dried to obtain granules.
  • the resulting granules were mixed with a disintegrant and then finally with sucrose fatty acid ester that was sieved through a sieve having a mesh size of 30.
  • the resulting final mixture was pressed using a tablet press (available from Sejong Pharmatech Co., Ltd., Korea) according to a common method to form tablets having a hardness of about 10 kp to about 15 kp.
  • Tablets including tenofovir disoproxil orotate (hereinafter, also referred to as "TDO") and a non-metallic salt disintegrant were prepared in the same manner as in Example 1, according to the compositions in Table 8, in which the amounts of ingredients are represented in milligram (mg).
  • Tablets including TDO and a metallic salt disintegrant were prepared in the same manner as in Comparative Example 1, according to the compositions in Table 9, in which the amounts of ingredients are represented in milligram (mg).
  • Tablets including TDO and a non-metallic salt lubricant were prepared in the same manner as in Example 5, according to the compositions in Table 10, in which the amounts of ingredients are represented in milligram (mg).
  • Tablets including TDO and a metallic salt lubricant were prepared in the same manner as in Example 24, according to the compositions in Table 11, in which the amounts of ingredients are represented in milligram (mg).
  • Table 12 shows the results with regard to Examples 1 to 4
  • Table 13 shows the results with regard to Examples 5 to 8
  • Table 14 shows the results with regard to Examples 9 to 12
  • Table 15 shows the results with regard to Examples 20 to 23
  • Table 16 shows the results with regard to Examples 24 to 27
  • Table 17 shows the results with regard to Comparative Examples 1 to 4
  • Table 18 shows the results with regard to Comparative Examples 5 to 8
  • Table 19 shows the results with regard to Comparative Examples 9 to 12
  • Table 20 shows the results with regard to Comparative Examples 13 to 16
  • Table 21 shows the results with regard to Comparative Examples 17 to 20.
  • the amounts of generated unknown related compounds A and B were about 5 times to about 50 times less when a non-metallic salt disintegrant and a non-metallic salt lubricant were used compared to the case when a metallic disintegrant was used alone or together with a metallic salt lubricant, which indicates that the tablets including a non-metallic salt disintegrant and a non-metallic salt lubricant had remarkably improved storage stability. Also, in the tablets prepared by dry granulation, the amounts of generated unknown related compounds A and B were less about 2 times up to about 20 times compared to the tablets prepared by wet granulation.
  • an allowable level of an unknown impurity with an unidentified structure is 0.2% and an allowable level of an impurity with an identified structure is 0.5%.
  • the tablets of Examples 1, 2, 5, and 6 including a non-metallic salt disintegrant and lubricant as excipients satisfied a 0.2% allowable level of the unknown impurity, while the tablets of Comparative Example 1, 2, 5, and 6 including metallic salt disintegrant or lubricant exceeded the allowable level.
  • TDP tenofovir disoproxil phosphate
  • Bioavailabilities of a compound represented by Formula A tenofovir, also referred to as T
  • a compound of Formula 1 tenofovir disoproxil, also referred to as TD
  • salts of the compound of Formula 1 i.e., tenofovir disoproxil fumarate (TDF), tenofovir disoproxil orotate (TDO), and tenofovir disoproxil phosphate (TDP) were evaluated according to the following method.
  • Sprague-Dawley rats as subjects were divided into 6 groups, each group including four rats.
  • Each of the test compounds in an amount equivalent to 4.3 mg of tenofovir was completely dissolved in purified water, and then orally administered into the rats using a 1-mL syringe. After the administration, about 0.3 mL of blood was taken from the jugular vein of each rat at each hour to obtain blood samples, followed by centrifugation to collect only plasma.
  • concentration of blood tenofovir in each blood sample was measured at each hour after the administration, and pharmacokinetic parameters of tenofovir (T) were analyzed. The results are shown in Table 24.
  • tenofovir (T) has a low bioavailability (BA) of about 9.90%, while tenofovir disoproxil (TD) developed to improve the low bioavailability of T has an improved bioavailability.
  • BA bioavailability
  • TD tenofovir disoproxil
  • TDP tenofovir disoproxil phosphate
  • each raw material was put in HDPE bottles together with 1 g of silica gel, and stored in a 60°C-chamber.
  • Unknown related compounds A and B as major decomposition products of the compound of Formula 1 were extracted after 2 weeks and 4 weeks from each sample with an extraction solution (including a pH 5.5 phosphate buffer solution, methanol, and butyl alcohol in a ratio of about 28:11:1), and the amounts thereof were analyzed by HPLC. The results are shown in FIG. 1 and Table 25.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne le phosphate de ténofovir disoproxil et une composition pharmaceutique comprenant du phosphate de ténofovir disoproxil ou un sel pharmaceutiquement acceptable de celui-ci, un délitant de sel non métallique et un lubrifiant de sel non-métallique lubrifiant.
EP15814377.6A 2014-07-01 2015-07-01 Phosphate de ténofovir disoproxil, et composition pharmaceutique de celui-ci comprenant un délitant de sel non métallique et un lubrifiant de sel non-métallique Withdrawn EP3154975A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140082137A KR20160003532A (ko) 2014-07-01 2014-07-01 테노포비어 디소프록실 인산염과, 비금속염 붕해제 및 비금속염 활택제를 포함하는 약학 조성물
PCT/KR2015/006766 WO2016003194A1 (fr) 2014-07-01 2015-07-01 Phosphate de ténofovir disoproxil, et composition pharmaceutique de celui-ci comprenant un délitant de sel non métallique et un lubrifiant de sel non-métallique

Publications (2)

Publication Number Publication Date
EP3154975A1 true EP3154975A1 (fr) 2017-04-19
EP3154975A4 EP3154975A4 (fr) 2018-01-03

Family

ID=55019641

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15814377.6A Withdrawn EP3154975A4 (fr) 2014-07-01 2015-07-01 Phosphate de ténofovir disoproxil, et composition pharmaceutique de celui-ci comprenant un délitant de sel non métallique et un lubrifiant de sel non-métallique

Country Status (3)

Country Link
EP (1) EP3154975A4 (fr)
KR (1) KR20160003532A (fr)
WO (1) WO2016003194A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101820084B1 (ko) * 2016-03-31 2018-01-18 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
EP3501506B1 (fr) * 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition de comprimé pharmaceutique comprenant du brexpiprazole
KR102254307B1 (ko) * 2019-04-03 2021-05-21 위더스제약주식회사 보관 안정성이 향상된 에페리손 약제학적 조성물
CN111407736A (zh) * 2020-03-30 2020-07-14 苏州弘森药业股份有限公司 一种富马酸替诺福韦二吡呋酯片的制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE305009T1 (de) 1997-07-25 2005-10-15 Gilead Sciences Inc Nukleotid-analog zusamensetzung und synthese verfahren
US20110009368A1 (en) * 2007-12-12 2011-01-13 Ultimorphix Technologies B.V. Solid forms of tenofovir disoproxil
WO2010142761A1 (fr) 2009-06-10 2010-12-16 Ultimorphix Technologies B.V. Succinate de ténofovir disoproxil
CN101781334B (zh) * 2010-03-04 2012-11-28 福建广生堂药业股份有限公司 替诺福韦酯的盐化合物，其制备方法和药物应用
US9187508B2 (en) * 2010-08-01 2015-11-17 Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Crystalline forms of tenofovir dipivoxil fumarate
WO2013132314A1 (fr) * 2012-03-05 2013-09-12 Laurus Labs Private Limited Phosphate de type ténofovir, procédés de préparation et composition pharmaceutique de celui-ci
KR101439255B1 (ko) 2012-08-30 2014-09-11 주식회사 종근당 테노포비어 디소프록실의 신규염 및 그의 제조방법
CN103830192A (zh) * 2012-11-27 2014-06-04 安徽贝克生物制药有限公司 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
EP2860184B1 (fr) * 2013-10-09 2018-08-29 Zentiva, k.s. Sel dihydrogénophosphate du Ténofovir disoproxil

Also Published As

Publication number Publication date
KR20160003532A (ko) 2016-01-11
WO2016003194A1 (fr) 2016-01-07
EP3154975A4 (fr) 2018-01-03

Similar Documents

Publication Publication Date Title
WO2015102400A1 (fr) Préparation composite pour une administration orale comportant de l'ézétimibe et de la rosuvastatine
WO2018070671A1 (fr) Composition de comprimé oral de lénalidomide
WO2016003194A1 (fr) Phosphate de ténofovir disoproxil, et composition pharmaceutique de celui-ci comprenant un délitant de sel non métallique et un lubrifiant de sel non-métallique
WO2019088669A1 (fr) Composition pour forme posologique solide orale présentant une désintégration améliorée et son procédé de préparation
WO2020242132A1 (fr) Comprimé gastrorésistant contenant du fumarate de diméthyle
WO2018111002A1 (fr) Comprimé à désintégration orale comprenant un composé de carbamate
WO2016114521A1 (fr) Composition de dutastéride sous forme de comprimé présentant une stabilité améliorée
WO2022098057A1 (fr) Procédé de préparation de particules cristallines d'acide 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylique, et composition pharmaceutique les comprenant
WO2012148181A2 (fr) Composition à libération contrôlée de médicaments
WO2018062964A1 (fr) Capsule composite contenant de la vitamine d ou un dérivé de celle-ci, et du raloxifène ayant un taux de dissolution amélioré, et son procédé de préparation
WO2019221488A1 (fr) Formulation pharmaceutique comprenant de l'apixaban et son procédé de préparation
WO2016159572A1 (fr) Formulation orale solide contenant de l'oseltamivir, et son procédé de préparation
WO2016114602A1 (fr) Nouvelle composition pharmaceutique
WO2014046312A1 (fr) Préparation orale et son procédé de fabrication
WO2022146089A1 (fr) Formulation orale solide pour le nettoyage du côlon
WO2022119300A1 (fr) Composition de dispersion solide d'olaparib avec stabilité et biodisponibilité améliorées
WO2018160011A1 (fr) Composition pharmaceutique présentant des caractéristiques améliorées de formation de comprimés selon le contrôle de taille des particules de pirfénidone, et son procédé de préparation
WO2021125824A1 (fr) Formulation pharmaceutique comprenant de la cibenzoline ou un sel de celle-ci
WO2018088830A1 (fr) Composition pharmaceutique sous forme de comprimé à matrice monolithique comprenant de la chlortalidone ou son sel et de l'amlodipine ou son sel et procédé de préparation associé
WO2010150984A2 (fr) Dispersion solide d'adefovir dipivoxil amorphe présentant une stabilité améliorée et son procédé de préparation
WO2018062941A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une démence et d'un dysfonctionnement cognitif, contenant du donépézil ou un sel de qualité pharmaceutique de celui-ci et de la mémantine ou un sel de qualité pharmaceutique de celle-ci, et son procédé de préparation
WO2017003112A1 (fr) Préparation solide à usage oral contenant du ténofovir disoproxil et son procédé de production
WO2019107989A1 (fr) Dispersion solide comprenant du fimasartan
WO2013187700A1 (fr) Formulation pharmaceutique combinée comprenant de la métformine et un inhibiteur de la hmg-coa réductase
EP3250199A2 (fr) Composition pharmaceutique pour le traitement de maladies gastro-intestinales

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161229

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20171201

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 473/34 20060101AFI20171127BHEP

Ipc: C07F 9/6561 20060101ALI20171127BHEP

Ipc: A61K 9/20 20060101ALI20171127BHEP

Ipc: A61P 31/12 20060101ALI20171127BHEP

Ipc: A61K 31/52 20060101ALI20171127BHEP

Ipc: C07F 9/02 20060101ALI20171127BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20190626